AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme

AZN BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Inquire About Class Action Investigation – AZN

NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.

AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH

AstraZeneca Plc's (NASDAQ: AZN) vaccine prospects were looking bright on Monday when the company reported its COVID-19 demonstrated 79% efficacy in Phase 3 U.S. trials. Then, sometime after midnight, U.S. officials took an unusual step of publicly questioning if that data was complete.

AstraZeneca Responds To NIAID Concerns Regarding COVID-19 Vaccine, Says Data As Of 17 Feb

AstraZeneca shares fell Tuesday after US health officials raised questions about the drug maker's COVID-19 vaccine, saying the company may have used some outdated trial data in its update about the formula. The Data and Safety Monitoring Board, an independent expert panel that monitors trial safety, said in a statement early Tuesday it was concerned that information released by AstraZeneca about its COVID-19 vaccine clinical trial "may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data."

AstraZeneca slips after independent data monitor questions potential use of 'outdated' data for vaccine trial (AZN)

Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.

Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?

AstraZeneca faces hurdles before entering the U.S. market.

Could These 2 Challenges Derail the AstraZeneca Vaccine?

The latest news could have a bigger impact in the rest of the world than in the U.S.

U.S. doubts hit AstraZeneca COVID-19 vaccine just as Europe resumes its rollout

Hello, Welcome to Insider Healthcare. I'm Blake Dodge, and I cover Big Tech for the healthcare team at Insider. Here's today's news:

AstraZeneca's latest COVID-19 vaccine setback

NIAID is headed by U.S. infectious diseases expert Dr. Anthony Fauci and is part of the National Institutes of Health.

AstraZeneca May Have Included ‘Outdated Information' in Vaccine Trial, NIAID Says

AstraZeneca may have used partially-outdated data when it reported promising US trial results on Monday, the US National Institute of Allergy and Infectious Diseases (NIAID) has said. An independent expert panel that monitors trial safety was "concerned" that the information released by AstraZeneca was "outdated," which may have provided "an incomplete view of the efficacy data," the NIAID said late Monday night, in a highly unusual statement.

AstraZeneca may have used outdated data in its US vaccine trial results, giving an 'incomplete view' of how well the shot worked, officials said

AstraZeneca Plc (NYSE: AZN) may have included outdated data related to the U.S. trials of its COVID-19 vaccine that resulted in an incomplete view of the efficacy data, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Monday. What Happened: The British drugmaker had said earlier that interim data from U.S. clinical trials in over 32,000 people shows its COVID-19 vaccine developed with Oxford University is 79% effective and safe.

NIAID Concerned AstraZeneca May Have Given Outdated Info From COVID-19 Vaccine US Trial

AstraZeneca PLC's (LON:AZN) trial results on the COVID-19 vaccine developed with Oxford University have been questioned by a US agency. The National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday that the pharma company should review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.

US agency asks AstraZeneca to review COVID-19 vaccine trial results

Drug firm may have provided incomplete view of efficacy data from US trial, says safety monitor

US agency questions AstraZeneca's Covid vaccine trial data

The U.S. government agency has urged AstraZeneca to review the efficacy data and ensure the most accurate, up-to-date data is made public.

AstraZeneca May Have Included “Outdated Information” In U.S. Trial Results, NIAID Says

The statement comes just one day after the findings of a large U.S. trial had shown the Oxford-AstraZeneca vaccine is safe and highly effective.

U.S. health agency casts doubt over AstraZeneca's Covid vaccine trial data

Results of a U.S. trial of AstraZeneca's COVID-19 vaccine may have included "outdated information," providing an "incomplete view of the efficacy data," said Federal health officials said early Tuesday.

U.S. health officials say AstraZeneca may have relied on ‘outdated information' over COVID-19 trial

AstraZeneca Plc (NASDAQ: AZN) says that it expects the European Medical Agency's (EMA) approval for a factory in the Netherlands later this month or early April. What Happened: According to Reuters, the facility has been at the center of a row between Britain and the European Union over COVID-19 vaccine supplies.

AstraZeneca Bullish On Receiving EU Approval For Dutch Factory By Early April: Reuters

There were no similar surge in vaccine fears for shots by Pfizer and Moderna.

European Trust In AstraZeneca's Covid-19 Shot Plummets Amid Politicized Blood Clot Scare

Jefferies healthcare analyst Peter Welford said the analysis of the AstraZeneca shot, published Monday, was better than expected.

Analysts cheer ‘surprisingly positive' AstraZeneca U.S. trial data

The COVID-19 vaccine of the U.K.-Swedish pharmaceuticals group AstraZeneca has shown robust results in its U.S. trial, the company said on Monday.

AstraZeneca's new COVID-19 vaccine trial data will give the shot a U.S. boost

AstraZeneca stock moved higher on Monday after its vaccine was shown to be 79% effective at stopping symptomatic Covid-19 in U.S. clinical trials.

AstraZeneca Vaccine Found to Be Safe and 79% Effective in U.S. Trial

The latest Phase III trial encompassed 32,000 participants, 21,583 of those receiving at least one dose of the AstraZeneca vaccine. The beleaguered AstraZeneca COVID-19 vaccine got a big shot in the arm, so to speak, today with results of the latest clinical trial which showed the vaccine is 79% effective against the virus.

AstraZeneca's COVID-19 vaccine has 79% efficacy in new U.S.-based trial

AstraZeneca Plc's (NASDAQ: AZN) says interim data from U.S. clinical trials in over 32,000 people shows its COVID-19 shot is 79% effective and safe. What Happened: The vaccine was also shown to be 100% effective at preventing severe disease, death, and hospitalization.

AstraZeneca's COVID-19 Shot Shows 79% Efficacy In US Trials

AstraZeneca says the large scale trials showed no safety concerns with regard to blood clots.

AstraZeneca Vaccine 100% Effective In Preventing Severe Disease And Hospitalizations, U.S. Trials Show

AstraZeneca PLC (LON:AZN) said the COVID-19 vaccine developed with Oxford University showed 100% efficacy against severe or critical disease and hospitalisation in late-stage trials. The FTSE 100 pharma company said the jab was well tolerated, and the independent data safety monitoring board (DSMB) identified no safety concerns related to the vaccine.

News for AstraZeneca Stock (AZN)